Class Action Lawsuit Filed Against Humacyte, Inc. Over Alleged Violations

Investors Urged to Join Lawsuit Filed by The Schall Law Firm

The Schall Law Firm, a national firm focused on shareholder rights, has announced a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) HUMA. This suit alleges violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 issued by the U.S. Securities and Exchange Commission.

Investors who acquired Humacyte’s securities during the period from May 10, 2024, to October 17, 2024 (the “Class Period”), are encouraged to reach out to the firm before January 17, 2025.

If you are a shareholder who incurred losses, click here to participate.

For further legal assistance, contact Brian Schall of the Schall Law Firm at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335. Additional communication options include visiting the firm’s website at www.schallfirm.com, or emailing bschall@schallfirm.com.

It’s important to note that the class in this case has not been certified yet. Until certification occurs, you will not be represented by an attorney. If you choose to take no action, you will remain an absent class member.

As stated in the complaint, Humacyte is accused of making false and misleading statements. The Company reportedly did not adhere to proper manufacturing practices, including microbial testing, at its Durham, North Carolina facility. As a result, the FDA’s review of the Company’s Biologic License Application (BLA) is expected to face delays while these manufacturing problems are rectified. These issues could jeopardize the FDA’s timely approval of the acellular tissue engineered vessel (“ATEV”), originally intended for vascular trauma treatment. Consequently, Humacyte’s public statements throughout the class period are considered to be misleading. When investors discovered the reality of Humacyte’s situation, they faced significant financial losses.

Consider joining the case to seek recovery for your losses.

The Schall Law Firm represents a global network of investors and specializes in securities class action lawsuits and shareholder rights.

Please be aware that this press release may qualify as Attorney Advertising in some jurisdictions based on applicable laws and ethical regulations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250117046742/en/

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com